Journal of Biological Chemistry
Volume 297, Issue 5, November 2021, 101266
Research ArticleEditors' PickExosome-mediated mRNA delivery in vivo is safe and can be used to induce SARS-CoV-2 immunity
Editors' Pick
Under a Creative Commons license
open access
Keywords
COVID19
spike
nucleocapsid
exosome
mRNA
cationic lipid
lipofection
antibody
T-cell
extracellular vesicles
Abbreviations
ACE2
angiotensin-converting enzyme II
BCA
bicinchoninic acid
BLI
bioluminescent imaging
CDM
chemically defined media
CTCS
clarified tissue culture supernatant
CVS
concentrated vesicle suspension
DOPE
dioleoyl phosphatidylethanolamine
DOTAP
dioleoyl-3-trimethylammonium propane
DTZ
diphenylterazine
ER
endoplasmic reticulum
EV
extracellular vesicle
HUVEC
human umbilical vein endothelial cell
LNP
lipid nanoparticle
NTA
nanoparticle tracking analysis
ORF
open reading frame
pfPBS
particle-free PBS
SARS-CoV-2
severe acute respiratory syndrome coronavirus 2
SEC
size-exclusion chromatography
Cited by (0)
Shang Jui Tsai is a graduate student working in the Department of Biological Chemistry at Johns Hopkins University. His research has two broad goals, one of which is to develop exosomes as a vehicle for delivering nucleic acid therapeutics, while the other is to develop genetically encoded modulators of neuronal signaling. His long-term goal is to develop novel therapeutics for the treatment of chronic pain and other neurological disorders.
- ‡
These authors contributed equally to this work.
© 2021 The Authors. Published by Elsevier Inc on behalf of American Society for Biochemistry and Molecular Biology.